News

Make sure you meet with us and discuss your projects and demands as well as new developments and service opportunities in person!

Please contact Luca Covello to arrange a meeting prior to the show.

Forthcoming Events

  • CPhI North America, May 16-18, 2017 Pennsylvania Convention Center Philadelphia, PA, USA (BOOTH 2253)
  • CF@BO 2017, June 4-6, 2017 Bologna, Italy
  • CPhI Worldwide, 24 - 26 October 2017 Messe Frankfurt, Germany  (STAND No: 40B40)

order by visits date title

8th CRYSTAL FORMS@BO CONVENTION

The 8th Bologna Convention on Crystal Forms Crystals in Food & Pharma - CF@BO 14-16 June 2015, Bologna, Italy OPENING - SUNDAY AT 2.00 pm - CHEMISTRY DEP. "G. CIAMICIAN" - Via Selmi, 2 - 40126 - Bologna. The AIC is supporting the registration to the workshop for two students and AIC members. Those willing to ask for a grant are kindly requested to send before April 15th, 2015 their CV and motivations to l.maini@unibo.it. REGISTRATION OPEN - Click Here FEES and VENUE - Click Here PROGRAMME - Click Here

Read all

IMAZAMOX: A Quest for Polymorphic Modifications of a Chiral and Racemic Herbicid

  ABSTRACT: The structure−property relationships of new polymorphs of the chiral herbicide imazamox were investigated by X-ray diffraction, hot stage microscopy (HSM), and differential scanning calorimetry (DSC). Four different polymorphs of imazamox(R) were found. The relationship between different crystal forms, relative thermal stability, and possible conversions pathways was explored. Racemic imazamox, for which no polymorphic modifications could be observed, was also characterized in the solid stat

Read all

Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment of major depres

Read all

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GE

Read all

Pagina 2 di 2
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb